Alison H. Banham

TL;DR: In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray.

TL;DR: This is the first description of circulating microRNAs and suggests that micro RNAs have potential as non‐invasive diagnostic markers for DLBCL and possibly other cancers.

TL;DR: Findings indicate that quantification of FOXP3-positive TR in breast tumors is valuable for assessing disease prognosis and progression, and that TR are an important therapeutic target for breast cancer.

TL;DR: The characterization of seven anti‐FOXP3 monoclonal antibodies enabling the detection of endogenous human FOXP3 protein by flow cytometry and immunohistochemistry indicate that the frequency ofFOXP3+ cells correlates with the level of expression of CD25 in naturally arising regulatory T cells and that FOXP 3 protein is expressed by some activated CD4+ and CD8+ T cell clones.

TL;DR: Assessing the relevance of regulatory T cells and CTLs present in the background of HL samples in the prognosis of a series of classic HL patients suggests that the variation of these markers over the course of the disease implies a possible role for them in the progression of HL cases.